Vγ9 Vδ2 T lymphocytes activation as a novel approach to test efficacy of different bisphosphonates

Endocrine

Volumn 48, Issue 1, 2015, Pages 346-348

  Rini, Giovam Battista ^a   Sprini, Delia ^a   Migliaccio, Silvia ^b   Basili, Stefania ^b   Strollo, Rocky ^c   Dieli, Francesco ^a   Napoli, Nicola ^d  

^a UNIVERSITY OF PALERMO   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; BONE DENSITY CONSERVATION AGENT;

AGED; BONE DENSITY; DRUG EFFECTS; FEMALE; HUMAN; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; T LYMPHOCYTE;

AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; HUMANS; LYMPHOCYTE ACTIVATION; LYMPHOCYTE COUNT; MIDDLE AGED; OSTEOPOROSIS; POSTMENOPAUSE; T-LYMPHOCYTES;

EID: 84939877351     PISSN: 1355008X     EISSN: 15590100     Source Type: Journal    
DOI: 10.1007/s12020-014-0303-1     Document Type: Letter

References (10)

1. M.J. Rogers, J.C. Crockett, F.P. Coxon, J. Mönkkönen, Biochemical and molecular mechanisms of action of bisphosphonates. Bone 49(1), 34–41 (2011)
2. J.F. Bukowski, C.C. Dascher, H. Das, Alternative bisphosphonate targets and mechanisms of action. Biochem. Biophys. Res. Commun. 328(3), 746–750 (2005)
3. K. Thompson, J.E. Dunford, F.H. Ebetino, M.J. Rogers, Identification of a bisphosphonate that inhibits isopentenyl diphosphate isomerase and farnesyl diphosphate synthase. Biochem. Biophys. Res. Commun. 290(2), 869–873 (2002)
4. M. Wilhelm, V. Kunzmann, S. Eckstein, P. Reimer, F. Weissinger, T. Ruediger, H.P. Tony, Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1), 200–206 (2003)
5. F. Dieli, N. Gebbia, F. Poccia, N. Caccamo, C. Montesano, F. Fulfaro, C. Arcara, M.R. Valerio, S. Meraviglia, C. Di Sano, G. Sireci, A. Salerno, Induction of Gamma delta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients invivo. Blood 102(6), 2310–2311 (2003)
6. V. Ferlazzo, C. Sferrazza, N. Caccamo, G. Di Fede, G. Di Lorenzo, M. D’Asaro, S. Meraviglia, F. Dieli, G. Rini, A. Salerno, In vitro effects of aminobisphosphonates on Vgamma9 Vdelta2 T cell activation and differentiation. Int. J. Immunopathol. Pharmacol. 19(2), 309–317 (2006)
7. R. Armamento-Villareal, N. Napoli, V. Panwar, D. Novack, Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis. N. Engl. J. Med. 355(19), 2048–2050 (2006)
8. R. Armamento-Villareal, N. Napoli, K. Diemer, M. Watkins, R. Civitelli, S. Teitelbaum, D. Novack, Bone turnover in bone biopsies of patients with low-energy cortical fractures receiving bisphosphonates: a case series. Calcif. Tissue Int. 85(1), 37–44 (2009)
9. N. Caccamo, F. Dieli, S. Meraviglia, G. Guggino, A. Salerno, Gammadelta T cell modulation in anticancer treatment. Curr. Cancer Drug Targets 10(1), 27–36 (2010)
10. S. Meraviglia, M. Eberl, D. Vermijlen, M. Todaro, S. Buccheri, G. Cicero, C. La Mendola, G. Guggino, M. D’Asaro, V. Orlando, F. Scarpa, A. Roberts, N. Caccamo, G. Stassi, F. Dieli, A.C. Hayday, In vivo manipulation of Vgamma9Vdelta2 T cells with zoledronate and low-dose interleukin-2 for immunotherapy of advanced breast cancer patients. Clin. Exp. Immunol. 161(2), 290–297 (2010)